This medicine is now known as tafasitamab.
On 15 January 2015, orphan designation (EU/3/14/1424) was granted by the European Commission to MorphoSys AG, Germany, for humanised Fc engineered monoclonal antibody against CD19 for the treatment of diffuse large B-cell lymphoma.
The sponsorship was transferred to Incyte Biosciences Distribution B.V., Netherlands, in July 2020.
Humanised Fc engineered monoclonal antibody against CD19, active ingredient tafasitamab
Treatment of diffuse large B-cell lymphoma
|Date of designation||
|Orphan designation status||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.